Background Although older patients with atrial fibrillation are at heightened risk of
thromboembolic and bleeding events, their optimal treatment choice remains uncertain …

In real-world clinical practice, underdosing, ie off-label use of reduced doses (RDs), of oral
factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial …

Abstract Direct Oral Anticoagulants (DOACs) consistently demonstrated a greater net clinical
benefit compared to Vitamin K Antagonists (VKAs) also in persons aged 75 years and over …

Background: The publication of high-quality observational studies (OSs) has fueled
reassessment of the treatment effects of direct oral anticoagulants (DOACs) in the elderly …

Background: Many publications have compared various outcomes defining safety and
efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Background Data on non-vitamin K antagonist oral anticoagulant (NOAC) use in patients
with atrial fibrillation (AF) and a history of falls are limited. Therefore, we investigated the …

Background Increasing age predisposes patients with atrial fibrillation to both
thromboembolic and bleeding events; however, data on outcomes of very elderly patients …

Background Frail patients with atrial fibrillation (AF) are thought to be at a higher risk for
cerebral infarction and death than patients who are not frail, making preventive interventions …

Patients aged≥ 65 years not only account for the majority of patients with atrial fibrillation
(AF) and venous thromboembolism (VTE), they are also at a higher risk of morbidity …